BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 15922328)

  • 1. Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase.
    Yang H; Burke T; Dempsey J; Diaz B; Collins E; Toth J; Beckmann R; Ye X
    FEBS Lett; 2005 Jun; 579(16):3385-91. PubMed ID: 15922328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores.
    Ditchfield C; Johnson VL; Tighe A; Ellston R; Haworth C; Johnson T; Mortlock A; Keen N; Taylor SS
    J Cell Biol; 2003 Apr; 161(2):267-80. PubMed ID: 12719470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule inhibition of Aurora kinases triggers spindle checkpoint-independent apoptosis in cancer cells.
    Sun L; Li D; Dong X; Yu H; Dong JT; Zhang C; Lu X; Zhou J
    Biochem Pharmacol; 2008 Mar; 75(5):1027-34. PubMed ID: 18163976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trivalent dimethylarsenic compound induces histone H3 phosphorylation and abnormal localization of Aurora B kinase in HepG2 cells.
    Suzuki T; Miyazaki K; Kita K; Ochi T
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):275-82. PubMed ID: 19716834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aurora kinases: new targets for cancer therapy.
    Carvajal RD; Tse A; Schwartz GK
    Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aurora kinase inhibitors as anti-cancer therapy.
    Lok W; Klein RQ; Saif MW
    Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.
    Zhang L; Zhang S
    J Obstet Gynaecol Res; 2011 Jun; 37(6):591-600. PubMed ID: 21159048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validating Aurora B as an anti-cancer drug target.
    Girdler F; Gascoigne KE; Eyers PA; Hartmuth S; Crafter C; Foote KM; Keen NJ; Taylor SS
    J Cell Sci; 2006 Sep; 119(Pt 17):3664-75. PubMed ID: 16912073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Live cell imaging reveals plant aurora kinase has dual roles during mitosis.
    Kurihara D; Matsunaga S; Uchiyama S; Fukui K
    Plant Cell Physiol; 2008 Aug; 49(8):1256-61. PubMed ID: 18593743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproliferative effect of Aurora kinase targeting in mesothelioma.
    Crispi S; Fagliarone C; Biroccio A; D'Angelo C; Galati R; Sacchi A; Vincenzi B; Baldi A; Verdina A
    Lung Cancer; 2010 Dec; 70(3):271-9. PubMed ID: 20371132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for Cdc48/p97 and Aurora B in controlling chromatin condensation during exit from mitosis.
    Meyer H; Drozdowska A; Dobrynin G
    Biochem Cell Biol; 2010 Feb; 88(1):23-8. PubMed ID: 20130676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora kinase inhibitors.
    Kitzen JJ; de Jonge MJ; Verweij J
    Crit Rev Oncol Hematol; 2010 Feb; 73(2):99-110. PubMed ID: 19369091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora A: target invalidated?
    Cochran AG
    Chem Biol; 2008 Jun; 15(6):525-6. PubMed ID: 18559262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and biological evaluation of a novel aurora A kinase inhibitor.
    Sardon T; Cottin T; Xu J; Giannis A; Vernos I
    Chembiochem; 2009 Feb; 10(3):464-78. PubMed ID: 19199284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Aurora kinase inhibitor patents.
    Coumar MS; Cheung CH; Chang JY; Hsieh HP
    Expert Opin Ther Pat; 2009 Mar; 19(3):321-56. PubMed ID: 19441907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of an Aurora-C kinase-deficient mutant disrupts the Aurora-B/INCENP complex and induces polyploidy.
    Chen HL; Tang CJ; Chen CY; Tang TK
    J Biomed Sci; 2005; 12(2):297-310. PubMed ID: 15917996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension.
    Lens SM; Wolthuis RM; Klompmaker R; Kauw J; Agami R; Brummelkamp T; Kops G; Medema RH
    EMBO J; 2003 Jun; 22(12):2934-47. PubMed ID: 12805209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells.
    Kaestner P; Stolz A; Bastians H
    Mol Cancer Ther; 2009 Jul; 8(7):2046-56. PubMed ID: 19584233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with aurora kinase inhibitors: a review.
    Boss DS; Beijnen JH; Schellens JH
    Oncologist; 2009 Aug; 14(8):780-93. PubMed ID: 19684075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RINGO C is required to sustain the spindle-assembly checkpoint.
    Mourón S; de Cárcer G; Seco E; Fernández-Miranda G; Malumbres M; Nebreda AR
    J Cell Sci; 2010 Aug; 123(Pt 15):2586-95. PubMed ID: 20605920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.